Receptor specific atrial natriuretic peptides
US6525022B1 · kind B1 · utility
26Cited by
25References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 16, 1998 |
| Grant date | Feb 25, 2003 |
| Priority date | — |
| Expiry date | Sep 16, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.